Generated by Meeveem AI
"Advancing precision biomarker detection from research to diagnostics with unmatched sensitivity"
Quanterix develops ultra-sensitive biomarker detection technology for healthcare and research. The company's platforms enable precision measurement of proteins in blood, cerebrospinal fluid, and tissue at unprecedented sensitivity levels, supporting neurology, oncology, immunology, and other disease areas where early detection and monitoring matter. Through dual modality analysis combining liquid and spatial proteomics, Quanterix delivers validated biomarker insights used in clinical trials, diagnostics development, and precision medicine. The technology supports pharmaceutical companies, research institutions, and diagnostic laboratories worldwide in advancing from discovery to clinical application.
471
Team Members
2007
Founded
Diagnostics
Sector
Hybrid
Work Environment
A future where precision biomarkers enable early disease detection, prevention, and personalised treatment, transforming healthcare from reactive intervention to proactive health management
At Quanterix, our mission is to transform healthcare by accelerating biomarker breakthroughs from discovery to diagnostics